Literature DB >> 12084027

The Hong Kong index of dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia.

Wayne H C Hu1, Kwok-fai Lam, Yeuk Hing Wong, Cindy L K Lam, Wai Mo HUIi, Kam-chuen Lai, Benjamin C Y Wong, Shiu-kum Lam.   

Abstract

AIM: Locally validated symptom questionnaires are essential instruments in dyspepsia research. A symptom score for Chinese dyspeptics was developed. Multiple aspects of validity and reliability were assessed.
METHODS: Sixty-five patients with endoscopy-negative dyspepsia and 65 healthy controls were presented with a list of 24 previously determined common abdominal symptoms and asked to rate the severity in a five point Likert scale. Comprehensibility and relevance of symptoms were assessed. The questionnaire was administered 3 h later to assess for reproducibility. A locally validated Short Form-36 quality-of-life questionnaire was also administered. Cisapride 5 mg thrice daily was prescribed to dyspeptic patients but not to the controls. The dyspepsia symptom and SF-36 questionnaires were repeated after 3 weeks for patients under treatment. Global change in symptoms and the need for further medical care were assessed. Concept, content, construct and criterion validity, consistency and reproducibility of the dyspepsia symptom questionnaire were assessed.
RESULTS: All items were considered comprehensible by more than 90% of subjects. Relevance of individual symptoms to dyspeptic patients ranged from 10.8-76.9%. Twelve items were selected by logistic regression to account for most of the differences between control and dyspeptic patients. Test-retest reproducibility and internal consistency were good with the intraclass correlation coefficient of 0.89 and Cronbach's alpha coefficient of 0.90. A cut-off score of equal to or greater than 16 was determined to discriminate between controls and dyspeptic patients. The dyspepsia score correlated negatively with all domains of the SF-36 quality of life scale except physical functioning. The dyspepsia questionnaire also discriminated between patients who reported a subjective improvement in symptoms and those who reported no change or worsening.
CONCLUSIONS: The dyspepsia symptom index was easy to understand, internally consistent and reproducible. It predicted global symptom change, and the symptom severity scores correlated negatively with quality of life. Copyright 2002 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Year:  2002        PMID: 12084027     DOI: 10.1046/j.1440-1746.2002.02713.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  16 in total

Review 1.  Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database.

Authors:  Puja Khanna; Nikhil Agarwal; Dinesh Khanna; Ron D Hays; Lin Chang; Roger Bolus; Gil Melmed; Cynthia B Whitman; Robert M Kaplan; Rikke Ogawa; Bradley Snyder; Brennan Mr Spiegel
Journal:  Am J Gastroenterol       Date:  2013-12-17       Impact factor: 10.864

2.  Comparison between empirical prokinetics, Helicobacter test-and-treat and empirical endoscopy in primary-care patients presenting with dyspepsia: a one-year study.

Authors:  Wayne H C Hu; S K Lam; Cindy L K Lam; W M Wong; K F Lam; K C Lai; Y H Wong; Benjamin C Y Wong; Annie O O Chan; C K Chan; Gabriel M Leung; W M Hui
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

3.  A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire.

Authors:  Luigi Gatta; Paul Moayyedi; Cesare Tosetti; Nimish Vakil; Enzo Ubaldi; Patrizia Barsanti; Giulia Fiorini; Valentina Castelli; Carlo Gargiulo; Paolo Lucarini; Maurizio Lera; Enkleda Kajo; Francesco Di Mario; Dino Vaira
Journal:  Intern Emerg Med       Date:  2010-10-01       Impact factor: 3.397

4.  Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups?

Authors:  Yao-Chun Hsu; Jyh-Ming Liou; Tzeng-Huey Yang; Wei-Lun Hsu; Hwai-Jeng Lin; Huei-Tang Wu; Jaw-Town Lin; Hsiu-Po Wang; Ming-Shiang Wu
Journal:  J Gastroenterol       Date:  2010-10-19       Impact factor: 7.527

5.  Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.

Authors:  W M Wong; B C Y Wong; W K Hung; Y K Yee; A W C Yip; M L Szeto; F M Y Fung; T S M Tong; K C Lai; W H C Hu; M F Yuen; S K Lam
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study.

Authors:  Victoria P Y Tan; Tin K Cheung; Wai M Wong; Roberta Pang; Benjamin C Y Wong
Journal:  World J Gastroenterol       Date:  2012-11-14       Impact factor: 5.742

7.  Dyspepsia in Turkish patients on continuous ambulatory peritoneal dialysis.

Authors:  Mustafa Altay; Faruk Turgut; Hatice Akay; Mehmet Kanbay; Aysegul Babali; Ali Akcay; Murat Duranay; Ramazan Yigitoglu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2008-01-15       Impact factor: 2.370

8.  Patient-reported outcomes in gastroenterology: clinical and research applications.

Authors:  Brennan M R Spiegel
Journal:  J Neurogastroenterol Motil       Date:  2013-04-16       Impact factor: 4.924

9.  Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction.

Authors:  Uday C Ghoshal; Rajan Singh; Full-Young Chang; Xiaohua Hou; Benjamin Chun Yu Wong; Udom Kachintorn
Journal:  J Neurogastroenterol Motil       Date:  2011-07-13       Impact factor: 4.924

10.  Asian consensus report on functional dyspepsia.

Authors:  Hiroto Miwa; Uday C Ghoshal; Sutep Gonlachanvit; Kok-Ann Gwee; Tiing-Leong Ang; Full-Young Chang; Kwong Ming Fock; Michio Hongo; Xiaohua Hou; Udom Kachintorn; Meiyun Ke; Kwok-Hung Lai; Kwang Jae Lee; Ching-Liang Lu; Sanjiv Mahadeva; Soichiro Miura; Hyojin Park; Poong-Lyul Rhee; Kentaro Sugano; Ratha-Korn Vilaichone; Benjamin Cy Wong; Young-Tae Bak
Journal:  J Neurogastroenterol Motil       Date:  2012-04-09       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.